Children’s Tumor Foundation

Patients: Empowered Clients
Our Focus - Neurofibromatosis

2,5 million patients worldwide! NF1, NF2, schwannomatosis Tumors
CTF Ambition: ‘Now’ ‘Fast’ ‘Together’

- Global Connector
- System Disruptor
- De-risker
Global Connector – value proposition

- **PATIENTS**
  - Supporter/
  - Educator/
  - Empowerer

- **ACADEMIA**
  - Funder/
  - Convener

- **GOVERNMENT/REGULATORY**
  - Influencer

- **PHARMA & BIOTECH**
  - De-risker

CTF
System Disruptor: SYNODOS

From:
- Basic Research
- Translational Research
- Clinical Research

To:
- Patient’s Mission
- Data portal
- Basic, translational, clinical Research
De-risker for Pharma

- Preclinical Test System
- NF Clinic Network
- Target scan service
- Global: Clinicians & Patients
- Patient owned NF registry
- Patient Advisors/Reviewers
- Market Model
- Global Network Conference/Workshops
CTF IMPACT - Selumetinib: Registration trial
In 70% patients tumor shrink >20%

NEJM 2016, 375:2550
CTF Impact in Numbers

CTF investments from 2010 to 2015, totaling $26.6M have attracted more than $38.4M in follow-up funding

700 registrants at conference

15,000 citations of CTF publications this year

2 new NF pig models

54 clinics

116 preclinical trials
CTF Impact in Numbers

1st partnership with pharma

Over 100 Schwannomatosis samples

6,000 data sets in NF data portal

6 cell lines open to all!

40 labs work together
THANK YOU

abakker@ctf.org